| Name | Title | Contact Details |
|---|
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Mountain Health Network is a West Virginia-based not-for-profit health delivery system comprised of Cabell Huntington Hospital, a 303-bed teaching hospital for Marshall University Schools of Medicine, Pharmacy and Nursing; St. Mary`s Medical Center, a 393-bed teaching hospital that operates St. Mary`s Schools of Nursing, Respiratory Care and Medical Imaging; Hoops Family Children`s Hospital, a 72-bed pediatric specialty hospital within Cabell Huntington Hospital; HIMG, a 60-member multi-specialty physician group; and a management agreement with Pleasant Valley Hospital, a 101 acute-bed hospital. Mountain Health is committed to improving the health and well-being of over one million children and adults in 23 counties in West Virginia, southern Ohio, and eastern Kentucky through understanding, respecting, and meeting their needs.
Asteri Medical Systems is a Daytona Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Canadian Psychological Association is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
National Committee for Quality Assurance is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Washington, DC. To find more information about National Committee for Quality Assurance, please visit www.ncqa.org